FDA identifies 20 drugs that need approved risk eval, strategy

FDA identified 20 Rx drugs and biologics that must have an approved risk evaluation and mitigation strategy, including GlaxoSmith-Kline's Lotronex, Novartis' Clozaril, Cephalon's Actiq, Hoffmann-LaRoche's Accutane, Celgene's Revlimid and Thalomid, Danco's Mifeprex and Biogen Idec's Tysabri.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.